BioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 41,000 Shares of Stock

Posted by Brenda Bartman on Sep 14th, 2026

BioNTech SE Sponsored ADR (NASDAQ:BNTX – Get Free Report) CEO Ugur Sahin sold 41,000 shares of the firm’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $99.45, for a total value of $4,077,450.00. Following the completion of the sale, the chief executive officer directly owned 602,209 shares in the company, valued at approximately $59,889,685.05. The trade was a 6.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total transaction of $3,670,400.00.
On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Trading Up 2.2%

Shares of BNTX stock traded up $2.13 on Monday, reaching $98.86. 1,212,282 shares of the stock were exchanged, compared to its average volume of 1,111,191. BioNTech SE Sponsored ADR has a 1-year low of $79.52 and a 1-year high of $124.00. The stock has a market cap of $25.00 billion, a P/E ratio of -12.63 and a beta of 1.29. The company has a quick ratio of 7.80, a current ratio of 7.85 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $96.98 and a two-hundred day moving average of $95.27.

BioNTech (NASDAQ:BNTX – Get Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million for the quarter, compared to analyst estimates of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business’s revenue was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.60) earnings per share. On average, research analysts anticipate that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Trading of BioNTech

Several institutional investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP increased its position in shares of BioNTech by 17.3% in the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock worth $1,157,000 after purchasing an additional 1,833 shares during the last quarter. Integrated Wealth Concepts LLC bought a new stake in BioNTech in the second quarter valued at about $39,000. Nykredit A S acquired a new stake in BioNTech during the second quarter valued at approximately $293,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in BioNTech by 66.7% during the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,020,000 after buying an additional 4,390 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new position in shares of BioNTech in the 2nd quarter worth approximately $2,520,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

BNTX has been the topic of a number of research reports. BMO Capital Markets downgraded shares of BioNTech from an “outperform” rating to a “market perform” rating and cut their target price for the company from $128.00 to $105.00 in a research note on Tuesday, September 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research note on Monday, July 6th. Jefferies Financial Group reissued a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. UBS Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and increased their price objective for the company from $117.00 to $135.00 in a research report on Wednesday, May 27th. Finally, Morgan Stanley dropped their price target on shares of BioNTech from $126.00 to $119.00 and set an “overweight” rating on the stock in a research note on Wednesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $126.00.

Read Our Latest Stock Report on BioNTech

BioNTech Company Profile

(Get Free Report)

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.